Bill Text: FL S0706 | 2019 | Regular Session | Introduced
Bill Title: Institutional Pharmacies
Spectrum: Partisan Bill (Republican 1-0)
Status: (Failed) 2019-05-03 - Died in Health Policy [S0706 Detail]
Download: Florida-2019-S0706-Introduced.html
Florida Senate - 2019 SB 706 By Senator Bean 4-00744A-19 2019706__ 1 A bill to be entitled 2 An act relating to institutional pharmacies; amending 3 s. 465.003, F.S.; revising the definition of the term 4 “institutional formulary system”; amending s. 465.019, 5 F.S.; authorizing the use of an institutional 6 formulary system in a Class I institutional pharmacy; 7 specifying requirements for the policies and 8 procedures of an institutional formulary system in a 9 Class I institutional pharmacy; providing an effective 10 date. 11 12 Be It Enacted by the Legislature of the State of Florida: 13 14 Section 1. Subsection (7) of section 465.003, Florida 15 Statutes, is amended to read: 16 465.003 Definitions.—As used in this chapter, the term: 17 (7) “Institutional formulary system” means a method whereby 18 the medical staff evaluates, appraises, and selects those 19 medicinal drugs or proprietary preparations that,whichin the 20 clinical judgment of the medical staff,staff’s clinical21judgmentare most useful in patient care,andwhichare 22 available for dispensing by a practicing pharmacist for a Class 23 I institutional pharmacy, or a practicing pharmacist in a Class 24 II institutional pharmacy or a Class III institutional pharmacy, 25 as those terms are defined in s. 465.019(2). 26 Section 2. Subsection (6) of section 465.019, Florida 27 Statutes, is amended, subsection (7) is added to that section, 28 and paragraph (a) of subsection (2) of that section is 29 republished, to read: 30 465.019 Institutional pharmacies; permits.— 31 (2) The following classes of institutional pharmacies are 32 established: 33 (a) “Class I institutional pharmacies” are those 34 institutional pharmacies in which all medicinal drugs are 35 administered from individual prescription containers to the 36 individual patient and in which medicinal drugs are not 37 dispensed on the premises, except that nursing homes licensed 38 under part II of chapter 400 may purchase medical oxygen for 39 administration to residents. No medicinal drugs may be dispensed 40 in a Class I institutional pharmacy. 41 (6) In a Class I institutional pharmacy, a Class II 42 institutional pharmacy, or a Class III institutional pharmacy, 43 an institutional formulary system may be adopted with approval 44 of the medical staff for the purpose of identifying those 45 medicinal drugs, proprietary preparations, biologics, 46 biosimilars, and biosimilar interchangeables that may be 47 dispensed by a practicing pharmacist for a Class I institutional 48 pharmacy, or dispensed by a practicing pharmacist in a Class II 49 institutional pharmacy or a Class III institutional pharmacy, 50 who is employed by the institutional pharmacythe pharmacists51employed in such institution. A facility that haswitha Class I 52 institutional pharmacy permit, a Class II institutional pharmacy 53 permit, or a Class III institutional pharmacy permit which is 54 operating under the formulary system shall establish policies 55 and procedures for the development of the system, in accordance 56 with the joint standards of the American Hospital Association 57 and American Society of Hospital Pharmacists, for the use 58utilizationof an institutionala hospitalformulary system, 59 which mustformularyshallbe approved by the medical staff. 60 (7) The policies and procedures for an institutional 61 formulary system in a Class I institutional pharmacy must: 62 (a) Be approved by the medical staff. 63 (b) Openly provide detailed methods and criteria for the 64 selection and objective evaluation of all available 65 pharmaceuticals. 66 (c) Include policies for the development, maintenance, 67 approval, dissemination, and notification to prescribers of the 68 drug formulary and for continuous and comprehensive review of 69 formulary drugs. 70 (d) Provide for regular monitoring of compliance with the 71 policies and procedures and of clinical outcomes in 72 circumstances in which a substitution of drugs has occurred. 73 (e) Provide a mechanism to inform the prescriber prior to 74 any substitution of drugs by using a method of communication 75 designated by the prescriber for such purpose. The method of 76 communication designated by the prescriber must be noted in the 77 patient’s chart. 78 (f) Establish a process that allows any individual 79 prescriber to opt out of the formulary system. 80 (g) Establish a process that allows any individual 81 prescriber to opt out of the formulary system only with respect 82 to a particular patient. 83 (h) Include policies stating that practitioners will not be 84 penalized for prescribing nonformulary drug products that are 85 medically necessary. 86 (i) Be consistent with applicable state and federal laws 87 and with rules of the department and board. 88 Section 3. This act shall take effect July 1, 2019.